New antibody drug takes aim at rheumatoid arthritis in first human trial
Disease control
Not yet recruiting
This early-stage trial tests a new drug called KT502 in 27 adults with moderate to severe rheumatoid arthritis. The drug is designed to deplete certain immune cells (B cells) that contribute to joint inflammation. The main goal is to check safety and find the right dose, not yet …
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC